English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Is prescription of a therapy costing 150 000 CHF reason­ able? The costs of medicinal products have increased substan­ tially in the last decade. Access to medical innovations for all patients is in acute danger. This situation requires a political commitment by the wider community of care­ givers, healthcare providers and industry. New pricing models are inevitable to garantee access to medical innovation for all people in our society. Further, we must require companies to be more transparent when setting drug prices and require an attitude of con­ sensus on prices between these industries – financially sound. Finally, our health insurance system must accept some state control to avoid patient selection, but also know the precise margin of manoeuvre over time in terms of cost expenditures assigned to oncology.

«Ist die Verordnung einer Therapie von 150 000 CHF vertretbar?»